AI blood test could spot lung cancer return earlier
NCT ID NCT07291921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether advanced blood tests and artificial intelligence can help detect lung cancer recurrence earlier and without invasive procedures. About 100 adults who had surgery for stage IB-IIIA lung cancer and received standard chemo-immunotherapy before surgery will provide blood samples over time. The goal is to build a better monitoring system to catch any remaining or returning cancer sooner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?